STOCK TITAN

Stereotaxis (STXS) Stock News

STXS NYSE

Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.

News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.

Rhea-AI Summary

Stereotaxis (STXS) reported third-quarter 2026 revenue of $8.925 million, with growth in systems and recurring revenue compared with last year. Revenue rose 20% year over year and 16% sequentially. Systems revenue reached $2.976 million; recurring revenue was $5.949 million, up 6% annually but down 4% sequentially. Supply constraints left approximately $1.9 million in disposable orders unconverted to revenue entering the fourth quarter.

Gross margin was 45%, and net loss was $6.482 million versus $6.463 million a year earlier. Quarter-end cash was $3.976 million. A convertible note financing of up to $24 million includes an initial $12 million closing and another $12 million available at the company's option following certain regulatory milestones. Pro forma cash would be $16 million. Stereotaxis also completed its Robocath acquisition and announced a Canon collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.62%
Tags
-
Rhea-AI Summary

Stereotaxis (NYSE: STXS) has signed definitive agreements with investors for convertible note financing of up to $24 million. The financing includes an initial upfront closing of $12 million and an additional $12 million available at the company's option following certain regulatory milestones.

The notes carry 10% annual interest, accrued and due at maturity in three years. They may convert into common stock at $1.21 per share, a 30% premium to the 10-day volume-weighted average share price before closing. Pro forma cash and cash equivalents are $16 million, with access to an additional $12 million bringing total availability to $28 million. Stereotaxis believes the financing bridges it to profitability. Net proceeds will support working capital, product commercialization, research and development, and other general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.62%
Tags
none
-
Rhea-AI Summary

Stereotaxis (STXS) announced first-in-human study results showing 100% clinical success for subsidiary Robocath’s next-generation robotic system in coronary interventions.

The prospective pilot enrolled 20 patients undergoing percutaneous coronary intervention, a procedure to open narrowed coronary arteries. Technical success was 95%, with all but one procedure completed entirely robotically without conversion to manual. No device-related adverse events were reported through 30-day follow-up. The study included several levels of lesion complexity, and operating physicians had no fluoroscopy radiation exposure. Findings were presented at TCT on November 1, 2026; a manuscript is under review. Stereotaxis plans to progress the technology toward regulatory submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
Rhea-AI Summary

Stereotaxis (NYSE: STXS) and Canon Medical Systems USA announced a technology compatibility and commercial collaboration pairing their robotic navigation and imaging systems. The companies are collaborating to offer Canon’s Alphenix interventional imaging platform alongside Stereotaxis’ GenesisX Robotic Magnetic Navigation system in a compatible configuration.

Alphenix provides imaging and workflow capabilities for interventional cardiology. GenesisX navigates interventional catheters robotically and is designed for use in existing catheterization labs without construction. The companies aim to give hospitals more flexibility when planning robotic electrophysiology labs and will explore workflow improvements and additional capabilities. Their technologies will be presented at TCT 2026 in Canon’s booth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none
-
Rhea-AI Summary

Stereotaxis (STXS) announced that Pauls Stradiņš Clinical University Hospital in Riga has installed Latvia’s first robotic magnetic navigation system for treating cardiac arrhythmias.

The hospital has successfully treated initial patients with a broad range of arrhythmias using the Genesis Robotic Magnetic Navigation System. The system is used in cardiac ablation, a minimally invasive procedure to treat abnormal heart rhythms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
-
Rhea-AI Summary

Stereotaxis (STXS) will release its third-quarter 2026 financial results after U.S. financial markets close on November 10, 2026. A conference call and webcast will follow at 4:30 p.m. ET to discuss results and corporate developments. Live and replay webcasts will be available through the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
earnings date
Rhea-AI Summary

Stereotaxis (STXS) will showcase its digital and robotic technologies at Heart Rhythm Society’s HRX conference in Atlanta on September 18-20, 2026.

The company will feature Synchrony, an integrated lab display, and SynX, a cloud-based connectivity platform, alongside discussions and hands-on experiences on the future of cardiovascular care. Chairman and CEO David Fischel will join the main-stage panel “Autonomous and Assistive EP Procedural Systems” on September 19 at 11:35 a.m. EDT to discuss autonomous EP technologies. Synchrony, which received FDA clearance earlier in 2026, is already in use at multiple clinical sites in the US and Europe and is provided with SynX for secure remote collaboration, recording and monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
AI
-
Rhea-AI Summary

Stereotaxis (STXS)/b) announced that the University of Szeged in Hungary has treated over 70 arrhythmia patients with the Genesis Robotic Magnetic Navigation system just over one month after launching its robotic cardiology program in July.The Electrophysiology team at the Szent-Györgyi Albert Clinical Center, led by Prof. Tamás Szili-Török, has used the system for a broad range of arrhythmias, including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia. Early cases included complex single arm-access procedures and treatments of patients with multiple previous failed ablations that the hospital states were not successfully treatable without robotics. The University of Szeged is the first hospital in Hungary with a robotic cardiology program and plans to celebrate the grand opening at a scientific symposium on September 8.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Stereotaxis (NYSE: STXS) reported 2026 second quarter revenue of $7.7 million, down from $8.8 million a year earlier, with systems revenue at $1.5 million and recurring revenue at $6.2 million. Robotic catheter revenue surpassed $1 million, growing 270% sequentially, supported by initial Synchrony digital operating room sales following FDA clearance in April.

Gross margin was 58%, including 66% on recurring revenue and 29% on systems. Operating expenses were $9.1 million, including $2.5 million of non-cash charges, resulting in a net loss of $4.5 million. Negative free cash flow was $3.7 million. At June 30, 2026, the company held $10.5 million in cash and had no debt. Stereotaxis completed its previously announced acquisition of Robocath and reported the first U.S. purchase of a GenesisX robotic system, expected to be installed this fall.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
Rhea-AI Summary

Mobia Medical (Nasdaq: MOBI) appointed Myriam Curet, M.D. to its Board of Directors as an independent director, effective July 30, 2026. The company highlights her combination of clinical, executive and public company board experience to support its stroke recovery business.

Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine, holds a part-time clinical role at the Palo Alto VA Medical Center, and has previously held senior surgical posts at Stanford and the University of New Mexico. She also serves on the boards of Inspire Medical Systems (NYSE: INSP) and Stereotaxis (NYSE American: STXS) and is a Fellow of the American College of Surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
management

FAQ

What is the current stock price of Stereotaxis (STXS)?

Stereotaxis (STXS) last closed at $0.9461.

What is the market cap of Stereotaxis (STXS)?

The market cap of Stereotaxis (STXS) is approximately $95.4M.